A Double-blind, Phase 1, Single Ascending Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of BOS161721 in Healthy Subjects

Trial Profile

A Double-blind, Phase 1, Single Ascending Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of BOS161721 in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 04 May 2018

At a glance

  • Drugs BOS 161721 (Primary) ; BOS 161721 (Primary)
  • Indications Autoimmune disorders; Systemic lupus erythematosus
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Boston Pharmaceuticals
  • Most Recent Events

    • 30 Apr 2018 Status changed from active, no longer recruiting to completed.
    • 06 Feb 2018 Status changed from recruiting to active, no longer recruiting.
    • 10 Oct 2017 Planned End Date changed from 1 Apr 2018 to 12 Apr 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top